Never said that. You're thinking of 100 mg TC/week, where the 10 mg T/day is more than the vast majority of men would ever make naturally.
You failed to give the AI the context, which is the distinction between TRT dosing at 5 mg T/day (50 mg TC/week in divided doses) versus dosing that declines to as little as 2-3 mg T/day (50 mg TC/week in one dose). Here is the followup question in my AI thread:
Question to AI:
Given this information, is it reasonable to suggest that a majority of hypogonadal men who start testosterone replacement therapy at a dose of 5 mg/day of testosterone will see a resolution of such symptoms, even if they may not be optimized?
Answer:Yes, it is reasonable to suggest that a majority of properly diagnosed hypogonadal men (confirmed low morning total T + symptoms) starting a standard dose equivalent to ~5 mg/day systemic testosterone delivery (e.g., typical starting gel regimens like AndroGel 1% 5 g delivering ~50 mg testosterone topically, with ~10% nominal absorption) will experience at least partial resolution or meaningful improvement in threshold-dependent sexual symptoms like low libido/desire and reduced spontaneous/morning erections—even if the dose isn't fully titrated to "optimized" mid-normal levels.
Why This Holds Based on the Threshold Effect
The threshold/saturation model means that restoring T from frankly low levels (<8–12 nmol/L or <230–350 ng/dL) to low-normal range (~300–500+ ng/dL) is often sufficient for libido, sexual thoughts, spontaneous erections, and related function. Standard starting doses frequently achieve this in many men, especially those with moderate-to-severe deficiency.
- Clinical response rates: In real-world and trial data, ~60–70%+ of symptomatic hypogonadal men report noticeable improvements in libido, sexual desire/motivation, erections (especially spontaneous/morning), and overall sexual satisfaction within weeks to months on TRT. For example:
- One observational study found ~70% reported benefits in erections, libido, energy, and/or mood by 3 months, with ~63% continuing at 12 months with sustained subjective benefit.
- Gel studies (starting doses delivering normal-range T) showed rapid improvements in sexual function scores (e.g., within 30 days, sustained), with libido and desire often responding earliest (plateauing by ~3 weeks).
- Meta-analyses confirm small-to-moderate benefits on desire/libido and erectile function vs. placebo in hypogonadal men, with stronger effects when baseline T is lower.
- Dose relevance: Starting gels (e.g., 50 mg topical testosterone) typically raise levels into the low-to-mid normal range for many, aligning with the threshold. Not everyone normalizes perfectly on the initial dose (absorption varies), but enough do for majority symptom relief without immediate up-titration. Studies often allow adjustment (e.g., to 75–100 mg topical), but initial responses are common at entry doses.
"Majority" is a fair characterization, but individual results vary. Factors favoring better response include:
- Lower baseline T (clearer deficiency).
- Primarily sexual symptoms tied to T (vs. vascular/neurologic ED, where TRT helps desire more than rigid erections alone).
- No major comorbidities interfering (e.g., uncontrolled diabetes, obesity, medications).
Response is not 100%—some need dose titration, adjuncts (e.g., PDE5i for ED), or don't respond robustly due to other causes. Effects on pure erectile function can be more modest/partial than on desire.
Key Caveats and Clinical Context
- Not optimized ≠ ineffective: Many see benefits at low-normal T; further increases yield diminishing returns for sexual domains per the threshold data.
- Monitoring is essential: Guidelines recommend confirming low T (two morning totals), assessing symptoms, and titrating based on follow-up levels (~4–6 weeks) and response. Aim for mid-normal range overall, but sexual symptoms often improve earlier.
- Risks/benefits: TRT improves these symptoms in responders but carries risks (e.g., erythrocytosis, prostate monitoring). Not everyone qualifies or benefits.
- "Majority" evidence level: Supported by RCTs, meta-analyses, and observational data, though exact percentages vary by study population, definition of "resolution" (partial improvement vs. full normalization), and duration.
In summary, yes—it's a reasonable, evidence-aligned expectation for most hypogonadal men on a standard starting dose. Consult an experienced clinician for diagnosis, baseline labs, individualized dosing, and monitoring rather than self-management. Lifestyle factors (weight loss, exercise) often amplify benefits.
